Skip to content
Forensic Analysis · Pharmaceuticals & Biotechnology · as of Nov 8, 2026

Prestige Consumer Healthcare Inc. (PBH)

A forensic read on Prestige Consumer Healthcare Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

B · Sound & dependable
Forensic grade
Safe
Financial health
4.0
Distress distance
Clean
Earnings quality
2
Forensic signals
10.2%
ROE
-4.3%
Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Prestige Consumer Healthcare Inc. earns a B (Sound & dependable) forensic quality grade, and its balance-sheet distress test reads 4.0, placing it in the Safe zone. 2 forensic signals were flagged in its latest SEC filings, led by inventory days.

What the filings flag

114d
FY2025→FY2026
Inventory days. Days inventory outstanding moved from 104 to 114 FY2025→FY2026 (against cost of goods sold; inventory +8% vs -2% in cost of sales). Inventory is building a little faster than sales — watch for markdowns.
7.0%
FY2026
Return on invested capital. Return on invested capital is 7.0% in the latest fiscal year and steady across FY2024–FY2026, inside a 1.2-point range. After-tax operating profit was $260M in FY2024 and $229M in FY2026, with operating income at 30.4% of revenue in FY2024, 29.6% in FY2025 and 28.4% in FY2026. The capital base behind it cannot be compared across FY2024–FY2026: short-term debt is tagged in one of those two fiscal years and not the other, and an untagged line enters this calculation as zero, so any change in the base would be a change in what the filer tagged.

Key fundamentals

Latest Revenue$1.09B
Revenue Growth YoY-4.3%
Revenue CAGR (2yr)-1.6%
Net Margin17.5%
Free Cash Flow$246.4M
Return on Equity10.2%
Debt / Equity0.53x

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Prestige Consumer Healthcare Inc.'s actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Nov 8, 2026. Forensic signals flag probability, not certainty.

See a wrong number? Report an error with the filing it should match.